Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.
The intent of this Request for Proposal (RFP) is to support basic science, pre-clinical research and clinical research through a competitive grants program that advances medical knowledge of the role of ANGPTL3 in health and disease.
The following types of research projects are considered in scope and will be eligible for this program:
o Basic science, pre-clinical research and clinical research that aligns with the in-scope research topics (i.e., animal models, in vivo/in vitro studies)
o Animal experimentation related to human biology
o Translational studies
LOI due date: March 12, 2021